Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis

Cancer Cell

Volumn 4, Issue 5, 2003, Pages 393-403

  Joyce, Johanna A ^a   Laakkonen, Pirjo ^b,c   Bernasconi, Michele ^b,d   Bergers, Gabriele ^a   Ruoslahti, Erkki ^b   Hanahan, Douglas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYSTEINYLARGINYLGLYCYLARGINYLARGINYLSERYLTHREONINE; CYSTEINYLARGINYLSERYLARGINYLLYSYLGLYCINE; CYSTEINYLGLUTAMYLTYROSYLGLUTAMINYLLEUCYLASPARTYLVALYLGLUTAMIC ACID; CYSTEINYLLYSYLALANYLALANYLLYSYLASPARAGINYLLYSINE; CYSTEINYLLYSYLGLYCYLALANYLLYSYLALANYLARGININE; PEPTIDE; PEPTIDE LIBRARY; PHENYLALANYLARGINYLVALYLGLYCYLVALYLALANYLASPARTYLVALINE; PLATELET DERIVED GROWTH FACTOR B; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; ENDOTHELIUM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ISLET BETA CELL; PERICYTE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEQUENCE HOMOLOGY; SKIN TUMOR; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STEM CELL; TUMOR GROWTH; TUMOR MODEL; TUMOR VASCULARIZATION;

ANIMALIA;

EID: 0344185348     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00271-X     Document Type: Article

References (56)

1. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.
2. Arbeit J., Munger K., Howley P.M., Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol. 68:1994;4358-4368.
3. Bergers G., Hanahan D., Coussens L.M. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int. J. Dev. Biol. 42:1998;995-1002.
4. Bergers G., Javaherian K., Lo K.M., Folkman J., Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:1999;808-812.
5. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111:2003;1287-1295.
6. Bergsten E., Uutela M., Li X., Pietras K., Ostman A., Heldin C.-H., Alitalo K., Eriksson U. PDGF-D is a specific protease-activated ligand for the PDGF β-receptor. Nat. Cell Biol. 3:2001;512-516.
7. Betsholtz C., Karlsson L., Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays. 23:2001;494-507.
8. Bohme K., Li Y., Oh P.S., Olsen B.R. Primary structure of the long and short splice variants of mouse collagen XII and their tissue-specific expression during embryonic development. Dev. Dyn. 204:1995;432-445.
9. Borges E., Jan Y., Ruoslahti E. Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J. Biol. Chem. 275:2000;39867-39873.
10. Burg M.A., Pasqualini R., Arap W., Ruoslahti E., Stallcup W.B. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res. 59:1999;2869-2874.
11. Carmeliet P., Jain R. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257.
12. Clements J.M., Bawden L.J., Bloxidge R.E., Catlin G., Cook A.L., Craig S., Drummond A.H., Edwards R.M., Fallon A., Green D.R., et al. Two PDGF-B chain residues, arginine 27 and isoleucine 30, mediate receptor binding and activation. EMBO J. 10:1991;4113-4120.
13. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 420:2002;860-867.
14. Coussens L.M., Hanahan D., Arbeit J.M. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am. J. Pathol. 149:1996;1899-1917.
15. Efrat S., Linde S., Kofod H., Spector D., Delannoy M., Grant S., Hanahan D., Baekkeskov S. Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene. Proc. Natl. Acad. Sci. USA. 85:1988;9037-9041.
16. Ellerby H.M., Arap W., Ellerby L.M., Kain R., Andrusiak R., Rio G.D., Krajewski S., Lombardo C.R., Rao R., Ruoslahti E., et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5:1999;1032-1038.
17. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:1989;58-61.
18. Fulgham D.L., Widhalm S.R., Martin S., Coffin J.D. FGF-2 dependent angiogenesis is a latent phenotype in basic fibroblast growth factor transgenic mice. Endothelium. 6:1999;185-195.
19. Gohring W., Sasaki T., Heldin C.H., Timpl R. Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope. Eur. J. Biochem. 255:1998;60-66.
20. Hallman R.D., Mayer D.N., Berg E.L., Broermann R., Butcher E.C. Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev. Dyn. 202:1995;325-332.
21. Hanahan D. Heritable information of pancreatic beta-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 315:1985;115-122.
22. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
23. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156:2000;1363-1380.
24. Heldin C.H., Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79:1999;1283-1316.
25. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels. Role of tumor type and microenvironment Proc. Natl. Acad. Sci. USA. 95:1998;4607-4612.
26. Hoffman J.A., Giraudo E., Singh M., Zhang L., Inoue M., Porkka K., Hanahan D., Ruoslahti E. Cancer Cell. 4:2003;383-391. this issue.
27. Johnsson A., Heldin C.H., Wasteson A., Westermark B., Deuel T.F., Huang J.S., Seeburg P.H., Gray A., Ullrich A., Scrace G., et al. The c-sis gene encodes a precursor of the B chain of platelet-derived growth factor. EMBO J. 3:1984;921-928.
28. Laakkonen P., Porkka K., Hoffman J.A., Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8:2002;751-755.
29. LaRochelle W.J., Jeffers M., McDonald W.F., Chillakuru R.A., Giese N.A., Lokker N.A., Sullivan C., Boldog F.L., Yang M., Vernet C., et al. PDGF-D, a new protease-activated growth factor. Nat. Cell Biol. 3:2001;517-521.
30. Leppink D.M., Bishop D.K., Sedmak D.D., Henry M.L., Ferguson R.M., Streeter P.R., Butcher E.C., Orosz C.G. Inducible expression of an endothelial cell antigen on murine myocardial vasculature in association with interstitial cellular infiltration. Transplantation. 48:1989;874-877.
31. Leveen P., Pekny M., Gebre-Medhin S., Swolin B., Larsson E., Betsholtz C. Mice deficient for PDGF-B show renal, cardiovascular and hematological abnormalities. Genes Dev. 8:1994;1875-1887.
32. Lindahl P., Johansson B.R., Leveen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B deficient mice. Science. 277:1997;242-245.
33. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature. 411:2001;375-379.
34. Lopez T., Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 1:2002;339-353.
35. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., McDonald D.M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160:2002;985-1000.
36. Ngo C.V., Gee M., Akhtar N., Yu D., Volpert O., Auerbach R., Thomas-Tikhonenko A. An in vivo function for the transforming Myc protein. elicitation of the angiogenic phenotype Cell Growth Differ. 11:2000;201-210.
37. Oh S.P., Griffith C.M., Hay E.D., Olsen B.R. Tissue-specific expression of type XII collagen during mouse embryonic development. Dev. Dyn. 196:1993;37-46.
38. Ornitz D.M., Itoh N. Fibroblast growth factors. Genome Biol. 2:2001;3005. 1-3005.12.
39. Ostman A., Heldin C.H. Involvement of platelet-derived growth factor in disease. development of specific antagonists Adv. Cancer Res. 80:2001;1-38.
40. Ostman A., Andersson M., Hellman U., Heldin C.H. Identification of three amino acids in the platelet-derived growth factor (PDGF) B-chain that are important for binding to the PDGF-β receptor. J. Biol. Chem. 266:1991;10073-10077.
41. Parangi S., Dietrich W., Christofori G., Lander E.S., Hanahan D. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. Cancer Res. 55:1995;6071-6076.
42. Pasqualini R., Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 380:1996;364-366.
43. Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M., Stryhn A., Ashmun R.A., Shapiro L.H., Arap W., Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60:2000;722-727.
44. Plotnikov A.N., Schlessinger J., Hubbard S.R., Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell. 98:1999;641-650.
45. Porkka K., Laakkonen P., Hoffman J.A., Bernasconi M., Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl. Acad. Sci. USA. 99:2002;7444-7449.
46. Rajotte D., Arap W., Hagedorn M., Koivunen E., Pasqualini R., Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest. 102:1998;430-437.
47. Roberts W.G., Delaat J., Nagane M., Huang S., Cavenee W.K., Palade G.E. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am. J. Pathol. 153:1998;1239-1248.
48. Ruoslahti E. Specialization of tumour vasculature. Nat. Rev. Cancer. 2:2002;83-90.
49. Sato T.N., Qin Y., Kozak C.A., Audus K.L. Tie-1 and Tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc. Natl. Acad. Sci. USA. 90:1993;9355-9358.
50. Schlingemann R.O., Rietveld F.J., de Waal R.M., Ferrone S., Ruiter D.J. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am. J. Pathol. 136:1990;1393-1405.
51. Schlingemann R.O., Rietveld F.J., Kwaspen F., van de Kerkhof P.C., de Waal R.M., Ruiter D.J. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissues. Am. J. Pathol. 138:1991;1335-1347.
52. Somasundaram R., Schuppan D. Type I, II, III, IV, V, and VI collagens serve as extracellular ligands for the isoforms of platelet-derived growth factor (AA, BB, and AB). J. Biol. Chem. 271:1996;26884-26891.
53. Soriano P. Abnormal kidney development and hematological disorders in PDGFβ-receptor mutant mice. Genes Dev. 8:1994;1888-1896.
54. St. Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., Kinzler K.W. Genes expressed in human tumor endothelium. Science. 289:2000;1197-1202.
55. Thurston G., McLean J.W., Rizen M., Baluk P., Haskell A., Murphy T.J., Hanahan D., McDonald D.M. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest. 101:1998;1401-1413.
56. Yi M., Sakai T., Fassler R., Ruoslahti E. Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. Proc. Natl. Acad. Sci. USA. in press:2003.